NLS
Nordic Life Science is the leading nordic magazine within the life science sector.
- Website
- nordiclifescience.org · all feeds from this site
- Feed URL
https://nordiclifescience.org/feed/
Read it in your FeedListing reader
Or add to: Feedly Inoreader Raw feed
Latest posts
-
AstraZeneca launches USD 1.5 billion reinvestment program
AstraZeneca has started a three-year program, Reshaping for Sustainable Growth, that is expected to deliver USD 1.5 billion in annual pre-tax savings to be reinvested mainly in its pipeline. The company announced it alongside third-quarter results showing total revenue up 7% at…
-
BioInvent plans SEK 430 million rights issue
Swedish biotech BioInvent plans a rights issue of approximately SEK 430 million to fund development of its anti-TNFR2 antibody BI-1808 and its other priority programs. The company also proposes to cut up to 20 positions. The post BioInvent plans SEK 430 million rights issue…
-
Alligator sells mitazalimab to Biossil
Lund-based Alligator Bioscience has agreed to sell all rights and assets related to its CD40 agonist antibody mitazalimab to Biossil. The deal includes an upfront payment of USD 0.75 million, milestone payments of up to USD 108 million, and royalties on future sales. The post…
-
Bavarian Nordic to supply and donate mpox vaccines to new global stockpile
Bavarian Nordic will donate 75,000 doses of its MVA-BN mpox vaccine to a newly established global mpox vaccine emergency stockpile, and has also been awarded a contract to supply a further 150,000 doses. The post Bavarian Nordic to supply and donate mpox vaccines to new global…
-
There is no such thing as "scaled up"
How manufacturing challenges change as biotechnology moves from research to commercial supply. The post There is no such thing as "scaled up" appeared first on NLS .
-
Cantargia and Oncoinvent appoint new chief medical officers
Swedish Cantargia has appointed Monic Stuart, MD, as Chief Medical Officer, and Norwegian radiopharmaceutical company Oncoinvent has named Zuzana Jiráková Trnková, MD, PhD, to the same role. The post Cantargia and Oncoinvent appoint new chief medical officers appeared first on…
-
SenzaGen acquires UK immunotoxicology firm Alcyomics
Swedish SenzaGen has agreed to acquire Alcyomics, a UK company that tests drug candidates for immune-related side effects without using animals. The initial price is approximately SEK 28 million, and the deal takes SenzaGen into safety testing of biological drugs such as…
-
Evaxion wins International Prix Galien Award
Copenhagen-based Evaxion has won the 2026 International Prix Galien Award for best digital health solution for its AI-Immunology platform. It is the first time a Danish company has received the prestigious award. The post Evaxion wins International Prix Galien Award appeared…
-
Elicera co-founder awarded SEK 4 million for CAR-T research
Dr. Di Yu, co-founder of Uppsala-based Elicera Therapeutics, has received a grant of SEK 4 million from the Swedish Research Council to study how CAR-T cells can be designed to survive longer in the body and penetrate solid tumors more easily. The post Elicera co-founder awarded…
-
Glycorex moves into universal blood products
Glycorex Transplantation is broadening its strategy to develop standardized, universal blood products for civilian healthcare, emergency preparedness, and military medicine. The work will be carried out through its new subsidiary, Glycorex Universal Blood Products (UBP). The…
-
Sobi’s gout drug sustains uric acid reduction
Sobi’s pozdeutinurad significantly lowered serum uric acid levels in patients with uncontrolled gout, with the effect sustained for a full year, according to new Phase III data from the pivotal REDUCE-2 study. The results will be presented in a late-breaking session at ACR…
-
FDA to review Orexo’s nasal naloxone powder
The US Food and Drug Administration (FDA) has accepted Uppsala-based Orexo’s resubmitted New Drug Application for IZIPRY, a high-dose naloxone nasal powder for opioid overdose. A decision is expected by March 29, 2027. The post FDA to review Orexo’s nasal naloxone powder…
-
Genmab drug halves death risk in head and neck cancer
Copenhagen-based Genmab says its bispecific antibody petosemtamab, given with pembrolizumab, met both primary endpoints in the global Phase III LiGeR-HN1 trial in first-line recurrent or metastatic PD-L1-positive head and neck squamous cell carcinoma. The post Genmab drug halves…
-
ResoTher Pharma heads for Swedish listing
Following promising Phase IIa results in heart attack patients, the Danish biotech company ResoTher Pharma plans to list on Spotlight Stock Market in Sweden in December 2026. The listing will take place through a reverse takeover of Hunter Capital RTO 1, valuing the combined…
-
Vicore’s IPF trial passes futility analysis
Swedish biotech Vicore Pharma’s Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis (IPF) has passed a pre-planned futility analysis. The independent Data Monitoring Committee recommended that the trial continue without modification, and topline results remain…
-
Gentian posts record quarterly sales
Norwegian diagnostics company Gentian Diagnostics reported record third-quarter sales of NOK 51.1 million, up 22% from NOK 41.8 million a year earlier and 30% in currency-neutral organic terms. The post Gentian posts record quarterly sales appeared first on NLS .
-
Embla Medical narrows 2026 outlook
Icelandic mobility solutions company Embla Medical, parent of Össur, has narrowed its full-year 2026 guidance to around 5% organic sales growth, from a previous range of 5–7%, after slower growth in its Patient Care clinic network. The post Embla Medical narrows 2026 outlook…